You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR DANICOPAN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DANICOPAN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03053102 ↗	Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Completed	Achillion, a wholly owned subsidiary of Alexion	Phase 2	2017-03-31	The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
NCT03053102 ↗	Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Completed	Achillion Pharmaceuticals	Phase 2	2017-03-31	The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
NCT03053102 ↗	Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Completed	Alexion Pharmaceuticals	Phase 2	2017-03-31	The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
NCT03108274 ↗	A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants	Completed	Achillion, a wholly owned subsidiary of Alexion	Phase 1	2017-04-18	The purpose of this study was to determine the potential drug interaction between danicopan (ACH-0144471) and midazolam, fexofenadine, and mycophenolate mofetil. This was a 3-part study, with each part being an open-label, fixed-sequence, 2-treatment study in healthy adult participants.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DANICOPAN

Condition Name

Chart
Table

Condition Name for DANICOPAN
Intervention	Trials
Healthy	13
C3 Glomerulonephritis	3
C3 Glomerulopathy	3
Dense Deposit Disease	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DANICOPAN
Intervention	Trials
Hemoglobinuria, Paroxysmal	5
Hemoglobinuria	5
Glomerulonephritis, Membranoproliferative	3
Glomerulonephritis	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DANICOPAN

Trials by Country

Map
Table

Trials by Country for DANICOPAN
Location	Trials
United States	47
Italy	9
United Kingdom	8
New Zealand	7
France	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DANICOPAN
Location	Trials
Arizona	6
Florida	3
Ohio	3
California	3
Texas	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DANICOPAN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DANICOPAN
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	8
Phase 1	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DANICOPAN
Clinical Trial Phase	Trials
Completed	17
Recruiting	3
Not yet recruiting	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DANICOPAN

Sponsor Name

Chart
Table

Sponsor Name for DANICOPAN
Sponsor	Trials
Alexion Pharmaceuticals	23
Achillion, a wholly owned subsidiary of Alexion	14
Achillion Pharmaceuticals	7
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DANICOPAN
Sponsor	Trials
Industry	47
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.